title: Recurrent ganglioglioma in adults treated with BRAF inhibitors.
abstract: Thirteen adult patients with temozolomide, surgery and radiation refractory ganglioglioma were screened for the BRAF V600E mutation. Three (23%) were found positive for the presence of the BRAF mutation and were treated with the BRAF inhibitor dabrafenib. Dabrafenib was well tolerated with no grade 3 or higher toxicity. The median number of cycles was 7 (a cycle was defined as 1 month of daily dabrafenib) and best response was stable disease in two patients and a partial response in one patient. Median progression-free survival was 7 months with a range of 4-10 months.
authors.affiliation: Department of Neurology/Division of Neuro-Oncology, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington, 825 Eastlake Avenue E, POB 19023, MS G4940, Seattle, WA 98109-1023, USA.
authors.forename: Marc C
authors.initials: MC
authors.lastname: Chamberlain
mesh_terms: D000328:Adult; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D018303:Ganglioglioma / Q000188:drug therapy* / Q000235:genetics; D018698:Glutamic Acid / Q000235:genetics; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D010091:Oximes / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics / Q000378:metabolism*; D014633:Valine / Q000235:genetics
chemical_list: D004791:Enzyme Inhibitors; D007093:Imidazoles; D010091:Oximes; D018698:Glutamic Acid; D048493:Proto-Oncogene Proteins B-raf; D014633:Valine; C561627:dabrafenib
keywords: BRAF V600E mutation; BRAF inhibitors; dabrafenib; ganglioglioma